A phase I/II study of the safety and activity of a microsphere formulation of KNI-272 in patients with HIV-1 infection
| Autor: | Duncan Churchill, P. M. Slade, J. N. Weber, M. Youle, Brian Gazzard |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
CD4-Positive T-Lymphocytes Male Microbiology (medical) Patient Dropouts Anti-HIV Agents HIV Infections Pharmacology Transaminase Cohort Studies Acquired immunodeficiency syndrome (AIDS) Pharmacokinetics Blood plasma medicine Humans HIV Protease Inhibitor Pharmacology (medical) Protease inhibitor (pharmacology) Adverse effect Dose-Response Relationship Drug biology business.industry Alanine Transaminase Middle Aged biology.organism_classification medicine.disease Microspheres CD4 Lymphocyte Count Treatment Outcome Infectious Diseases Area Under Curve Immunology Lentivirus HIV-1 RNA Viral business Oligopeptides |
| Zdroj: | Journal of Antimicrobial Chemotherapy. 47:353-355 |
| ISSN: | 1460-2091 |
| DOI: | 10.1093/jac/47.3.353 |
| Popis: | Eighteen patients with symptomatic HIV disease were enrolled into a phase I/II study of a microsphere formulation of the HIV protease inhibitor KNI-272, with doses escalated up to a maximum dose of 60 mg/kg/day. One patient developed reversible elevation in hepatic transaminase. The plasma half-life of the drug was very short, varying between 0.25 and 1.1 h. No consistent effect on plasma HIV RNA levels or CD4(+) lymphocyte counts was seen. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|